Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy

Core Viewpoint - Bayer and Soufflé Therapeutics have entered into a strategic collaboration and global licensing agreement to develop a heart-targeted small interfering RNA (siRNA) therapy for dilated cardiomyopathy, a rare form of heart disease [1] Company Collaboration - The partnership aims to leverage Soufflé Therapeutics' expertise in cell-selective genetic therapies to advance the development of the siRNA-based treatment [1] - This collaboration signifies Bayer's commitment to addressing unmet medical needs in the cardiovascular space [1] Therapeutic Focus - The targeted therapy will specifically address a rare subset of heart disease, highlighting the innovative approach to treating dilated cardiomyopathy [1] - The development of this siRNA therapy represents a significant advancement in genetic therapies for heart conditions [1]